Antileukaemia effect of rapamycin alone or in combination with daunorubicin on ph+ acute lymphoblastic leukaemia cell line

Hematological Oncology

Volumn 30, Issue 3, 2012, Pages 123-130

  Yang, Xi ^a   Lin, Juan ^a   Gong, Yuping ^a   Ma, Hongbing ^a   Shuai, Xiao ^a   Zhou, Ruiqing ^a   Guo, Yong ^a   Shan, Qingqing ^a   He, Guangcui ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Autophagy; Daunorubicin; MTOR signalling pathway; Ph+acute lymphoblastic leukaemia; Rapamycin

Indexed keywords

DAUNORUBICIN; MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; AUTOPHAGY; CANCER CELL CULTURE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ADULT; AUTOPHAGY; CELL DIVISION; CELL LINE, TUMOR; DAUNORUBICIN; DRUG SYNERGISM; HUMANS; K562 CELLS; NEOPLASM PROTEINS; PHAGOSOMES; PHOSPHORYLATION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN PROCESSING, POST-TRANSLATIONAL; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES; TUMOR STEM CELL ASSAY;

EID: 84866267909     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.1013     Document Type: Article

References (24)

1. Teachey DT, Grupp SA, Brown VI. Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies Brit J Haematol 2009; 145:569-580.
2. Plasschaert SL, Kamps WA, Vellenga E, de Vries EG, de Bont ES. Prognosis in childhood and adult acute lymphoblastic leukaemia: a question of maturation? Cancer Treat Rev 2004; 30: 37-51.
3. Radich JP. Philadelphia chromosome-positive acute lymphocytic leukemia. Hematol Onocol Clin N 2001; 15: 21-36.
4. Cobaleda C, Gutiérrez-Cianca N, Pérez-Losada J, et al. A primitive hematopoietic cell is the target for the leukemic transformation in human Philadelphia-positive acute lymphoblastic leukemia. Blood 2000; 95: 1007-1013.
5. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006; 124: 471-484.
6. Kuo HP, Lee DF, Chen CT, et al. ARD1 stabilization of TSC2 suppresses tumorigenesis through the mTOR signaling pathway. Science 2010; 3: 1-12.
7. Sparks CA, Guertin DA. Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy. Oncogene 2010; 29: 3733-3744.
8. Brown VI, Fang J, Alcorn K, et al. Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signaling. Proc Natl Acad Sci USA 2003; 100: 15113-15118.
9. Avellino R, Romano S, Parasole R, et al. Rapamycin stimulates apoptosis of childhood acute lymphoblastic leukemia cells. Blood 2005; 106: 1400-1406.
10. Kharas MG, Janes MR, Scarfone VM, et al. Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+leukemia cells. J Clin Invest 2008; 118: 3038-3050.
11. Hirase C, Maeda Y, Takai S, et al. Hypersensitivity of Ph-positive lymphoid cell lines to rapamycin: possible clinical application of mTOR inhibitor. Leukemia Res 2009; 33: 450-459.
12. Brown VI, Seif AE, Reid GS, Teachey DT, Grupp SA. Novel molecular and cellular therapeutic targets in acute lymphoblastic leukemia and lymphoproliferative disease Immunol Res 2008; 42:84-105.
13. Zhou YP. The calculation of ld50 in new drugs with software SPSS. Prog Pharm Sci 2003; 27: 314-316.
14. Wang DG, Wang ZP, Tian BQ, Li X, Li S, Tian Y. Two hour exposure to sodium butyrate sensitizes bladder cancer to anticancer drugs. Int J Urol 2008; 15: 435-441.
15. Janes MR, Limon JJ, So L, et al. Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat Med 2010; 16: 205-213.
16. McCubrey JA, Steelman LS, Abrams SL, et al. Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. Leukemia 2008; 22: 708-722.
17. Zeng Z, Sarbassov D, Samudio IJ, et al. Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood 2007; 109: 3509-3512.
18. Kim JH, Chu SC, Gramlich JL, et al. Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species. Blood 2005; 105: 1717-1723.
19. Jiang BH, Liu LZ. Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment. Drug Resist Update 2008; 11: 63-76.
20. Maiuri MC, Zalckvar E, Kimchi A, Kroemer G. Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nature 2007; 8: 741-752.
21. Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell 2008; 132: 27-42.
22. Rubinsztein DC, Gestwicki JE, Murphy LO, Klionsky DJ. Potential therapeutic applications of autophagy. Nat Rev Drug Discov 2007; 6: 304-312.
23. Crazzolara R, Bradstock KF, Bendall LJ. RAD001 (everolimus) induces autophagy in acute lymphoblastic leukemia. Autophagy 2009; 5: 727-728.
24. Janusa A, Linkea A, Cebula B, Robak T, Smolewski P. Rapamycin, the mTOR kinase inhibitor, sensitizes acute myeloid leukemia cells, HL-60 cells, to the cytotoxic effect of arabinozide cytarabine. Anti-Cancer Drug 2009; 20: 693-701.